Avectas-016 (1).jpg

Scientific Advisory Board

Professor Daniel G. Anderson
MIT, The Koch Institute, Langer Laboratory
Professor Anderson joined the Avectas Scientific Advisory Board in 2016 to advise on the development of our delivery technology platform. He is an Associate Professor of Chemical Engineering, a member of the Institute for Medical Engineering and Science, and the Koch Institute for Integrative Cancer Research at MIT. He received his PhD in molecular genetics from the University of California at Davis. At MIT, he pioneered the use of robotic methods for the development of smart bio-materials for drug delivery and medical devices. His work has led to the first methods of quick synthesis, formulation, analysis, and biological evaluation of large libraries of bio-materials for use in medical devices, cell therapy and drug delivery. In particular, the advanced drug delivery systems he has developed provide new methods for nano-particulate drug delivery, non-viral gene therapy, siRNA delivery and vaccines.

Professor Mark W. Lowdell
UCL, Royal Free Hospital London
Professor Lowdell is the Director of Cellular Therapy at University College London (UCL) and runs the largest of the GMP production units with over 600m2 of manufacturing space. He is the qualified person (QP) for release of Advanced Therapy Medicinal Products (ATMPs) for clinical trials. Initiating as well as being involved in 8 cell therapy trials at present, five of which are UK national trials. He has been an advisor to UK Government regulatory bodies on the regulation of ATMPs and is an accredited assessor for one of the UK Government departments. He has worked extensively on quality standards for ATMPs and is the UK National Representative to the board of JACIE, the professional body responsible for accreditation of haematotherapies across the EU. Dr Lowdell’s research is in the fields of immunotherapy of viral infections, tumor immunotherapy and advanced regenerative medicine.

Board of Directors

Mr. Eunan Maguire
Mr. Maguire co-founded Adapt Pharma and serves as its Chief Operating Officer. Mr. Maguire also served as Senior Vice President of Strategy & Corporate Development at Jazz Pharmaceuticals plc. Mr. Maguire served as the President of Azur Pharma, Inc. and was a Co-founder and President of North America Operations at Azur Pharma Public Limited Company. He was responsible for commercial, medical, legal and administrative activities in the US. Mr. Maguire also served as Senior Vice President of Corporate & Business Development of Azur Pharma Limited. He served as Vice President of Business Development at King Pharmaceuticals and as Vice President of Strategic Planning at Elan Corporation, plc. He has 17 years of experience in the identification, evaluation and execution of pharmaceutical transactions including asset acquisitions and divestments, capital market financing transactions, and corporate merger and acquisitions.

Dr. Mary Martin
Non-Executive Director
Dr. Martin, PhD has over 25 years’ experience in drug delivery technology and product development and commercialization. Most recently she has served as Senior Vice President Global Regulatory, Quality and R&D Project Management with Horizon Pharma. Dr. Martin has held senior leadership roles in Vidara Therapeutics, AGI Therapeutics and the drug delivery division of Elan. Dr. Martin holds a PhD in Pharmacology, a certificate in company direction (CERTIoD) from the Institute of Directors and a Certified Diploma in Accounting and Finance (ACCA).

Dr. Ann Brady
Non-Executive Director
Dr. Brady is President of Theravance Biopharma Ireland, a Board Member at AN2H Discovery, and formerly a Senior Executive at Shire Pharmaceuticals and Elan Pharmaceuticals. Dr. Brady graduated from Trinity College, Dublin and is a senior leader with excellent bio-pharma experience in both established and emerging markets. Dr. Brady has extensive expertise in corporate strategy, business development, product development, operations and commercial management gained in multinational and emerging bio-pharmaceutical organisations. She boosts strong business and financial acumen coupled with excellent technical, analytical and interpersonal skills with a proven track record in identifying and implementing successful business solutions.

Mr. Barry Leonard
Non-Executive Director
Mr. Leonard is an Engineer, Entrepreneur and Company Director. He founded and led Virtus Ltd, an OEM medical devices manufacturer serving global brands including Hill-Rom, Smith & Nephew, Patterson Dental and KCI. At its peak, Virtus employed 250 highly skilled individuals between its Irish and US FDA approved manufacturing sites. Virtus was part-acquired by DCC plc. and ultimately sold to Hillenbrand Industries Inc. in 2014. Mr. Leonard brings a wealth of manufacturing, medical devices and corporate strategy experience to the board.

Executive Team

Dr. Michael Maguire
Founder & Director, CEO
Dr. Maguire is President and CEO of Avectas, which he has led since its inception in 2012. He has 20 years of experience in the life sciences industry, serving as a founder, investor, director and business leader. Dr. Maguire graduated from Trinity College, Dublin, as a biomedical engineer and completed his PhD on local delivery to the lung. Dr. Maguire is focused on creating value by addressing challenges in delivery of advanced therapeutics.

Dr. Shirley O'Dea
Founder & Director, CSO
Dr. O’Dea co-founded Avectas in 2012 and is the company’s CSO. She is charged with overseeing scientific programs. Dr. O’Dea’s basic research provides a strong pipeline of applications for Avectas technology. Dr. O’Dea has previously served as a PI with Johnson & Johnson and has led a large academic group specialising is lung biology at National University of Ireland, Maynooth.